443 related articles for article (PubMed ID: 28988130)
21. Loss of pigment epithelium-derived factor: a novel mechanism for the development of endocrine resistance in breast cancer.
Jan R; Huang M; Lewis-Wambi J
Breast Cancer Res; 2012 Nov; 14(6):R146. PubMed ID: 23151593
[TBL] [Abstract][Full Text] [Related]
22. Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα-positive breast cancer.
Ciupek A; Rechoum Y; Gu G; Gelsomino L; Beyer AR; Brusco L; Covington KR; Tsimelzon A; Fuqua SA
Breast Cancer Res Treat; 2015 Nov; 154(2):225-37. PubMed ID: 26487496
[TBL] [Abstract][Full Text] [Related]
23. ERK/MAPK regulates ERRγ expression, transcriptional activity and receptor-mediated tamoxifen resistance in ER+ breast cancer.
Heckler MM; Thakor H; Schafer CC; Riggins RB
FEBS J; 2014 May; 281(10):2431-42. PubMed ID: 24684682
[TBL] [Abstract][Full Text] [Related]
24. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A
Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079
[TBL] [Abstract][Full Text] [Related]
25. Tumor-associated macrophages secrete CC-chemokine ligand 2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer.
Li D; Ji H; Niu X; Yin L; Wang Y; Gu Y; Wang J; Zhou X; Zhang H; Zhang Q
Cancer Sci; 2020 Jan; 111(1):47-58. PubMed ID: 31710162
[TBL] [Abstract][Full Text] [Related]
26. UBR5 over-expression contributes to poor prognosis and tamoxifen resistance of ERa+ breast cancer by stabilizing β-catenin.
Yang Y; Zhao J; Mao Y; Lin G; Li F; Jiang Z
Breast Cancer Res Treat; 2020 Dec; 184(3):699-710. PubMed ID: 32914356
[TBL] [Abstract][Full Text] [Related]
27. GPER promotes tamoxifen-resistance in ER+ breast cancer cells by reduced Bim proteins through MAPK/Erk-TRIM2 signaling axis.
Yin H; Zhu Q; Liu M; Tu G; Li Q; Yuan J; Wen S; Yang G
Int J Oncol; 2017 Oct; 51(4):1191-1198. PubMed ID: 28902352
[TBL] [Abstract][Full Text] [Related]
28. IGFBP-1 Expression Promotes Tamoxifen Resistance in Breast Cancer Cells via Erk Pathway Activation.
Zheng Y; Sowers JY; Houston KD
Front Endocrinol (Lausanne); 2020; 11():233. PubMed ID: 32435229
[TBL] [Abstract][Full Text] [Related]
29. A miR-26a/E2F7 feedback loop contributes to tamoxifen resistance in ER-positive breast cancer.
Liu J; Li X; Wang M; Xiao G; Yang G; Wang H; Li Y; Sun X; Qin S; Du N; Ren H; Pang Y
Int J Oncol; 2018 Oct; 53(4):1601-1612. PubMed ID: 30066905
[TBL] [Abstract][Full Text] [Related]
30. FGFR1 Is Associated With Tamoxifen Resistance and Poor Prognosis of ER-Positive Breast Cancers by Suppressing ER Protein Expression.
Lv Q; Guan S; Zhu M; Huang H; Wu J; Dai X
Technol Cancer Res Treat; 2021; 20():15330338211004935. PubMed ID: 33783288
[TBL] [Abstract][Full Text] [Related]
31. Keratinocyte growth factor (KGF) regulates estrogen receptor-alpha (ER-alpha) expression and cell apoptosis via phosphatidylinositol 3-kinase (PI3K)/Akt pathway in human breast cancer cells.
Chang HL; Sugimoto Y; Liu S; Wang LS; Huang YW; Ye W; Lin YC
Anticancer Res; 2009 Aug; 29(8):3195-205. PubMed ID: 19661335
[TBL] [Abstract][Full Text] [Related]
32. HNRNPA2B1 regulates tamoxifen- and fulvestrant-sensitivity and hallmarks of endocrine resistance in breast cancer cells.
Petri BJ; Piell KM; South Whitt GC; Wilt AE; Poulton CC; Lehman NL; Clem BF; Nystoriak MA; Wysoczynski M; Klinge CM
Cancer Lett; 2021 Oct; 518():152-168. PubMed ID: 34273466
[TBL] [Abstract][Full Text] [Related]
33. Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance.
Thomas NB; Hutcheson IR; Campbell L; Gee J; Taylor KM; Nicholson RI; Gumbleton M
Breast Cancer Res Treat; 2010 Feb; 119(3):575-91. PubMed ID: 19288272
[TBL] [Abstract][Full Text] [Related]
34. Nogo-B receptor increases the resistance to tamoxifen in estrogen receptor-positive breast cancer cells.
Gao P; Wang X; Jin Y; Hu W; Duan Y; Shi A; Du Y; Song D; Yang M; Li S; Han B; Zhao G; Zhang H; Fan Z; Miao QR
Breast Cancer Res; 2018 Sep; 20(1):112. PubMed ID: 30208932
[TBL] [Abstract][Full Text] [Related]
35. Tamoxifen resistance and metastasis of human breast cancer cells were mediated by the membrane-associated estrogen receptor ER-α36 signaling in vitro.
Gu W; Dong N; Wang P; Shi C; Yang J; Wang J
Cell Biol Toxicol; 2017 Apr; 33(2):183-195. PubMed ID: 27837347
[TBL] [Abstract][Full Text] [Related]
36. Dicer-mediated upregulation of BCRP confers tamoxifen resistance in human breast cancer cells.
Selever J; Gu G; Lewis MT; Beyer A; Herynk MH; Covington KR; Tsimelzon A; Dontu G; Provost P; Di Pietro A; Boumendjel A; Albain K; Miele L; Weiss H; Barone I; Ando S; Fuqua SA
Clin Cancer Res; 2011 Oct; 17(20):6510-21. PubMed ID: 21878538
[TBL] [Abstract][Full Text] [Related]
37. miR-489 Confines Uncontrolled Estrogen Signaling through a Negative Feedback Mechanism and Regulates Tamoxifen Resistance in Breast Cancer.
Soni M; Saatci O; Gupta G; Patel Y; Keerthi Raja MR; Li J; Liu X; Xu P; Wang H; Fan D; Sahin O; Chen H
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897675
[TBL] [Abstract][Full Text] [Related]
38. Downregulation of Choline Kinase-Alpha Enhances Autophagy in Tamoxifen-Resistant Breast Cancer Cells.
Kim HS; Tian L; Jung M; Choi SK; Sun Y; Kim H; Moon WK
PLoS One; 2015; 10(10):e0141110. PubMed ID: 26496360
[TBL] [Abstract][Full Text] [Related]
39. GPR30-mediated HMGB1 upregulation in CAFs induces autophagy and tamoxifen resistance in ERα-positive breast cancer cells.
Liu L; Liu S; Luo H; Chen C; Zhang X; He L; Tu G
Aging (Albany NY); 2021 Jun; 13(12):16178-16197. PubMed ID: 34182538
[TBL] [Abstract][Full Text] [Related]
40. Decreased chicken ovalbumin upstream promoter transcription factor II expression in tamoxifen-resistant breast cancer cells.
Riggs KA; Wickramasinghe NS; Cochrum RK; Watts MB; Klinge CM
Cancer Res; 2006 Oct; 66(20):10188-98. PubMed ID: 17047084
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
